HYPERFINE Q3 '26 Earnings Call - HYPERFINE INC

Explicit Guidance:

• 2026 Full-Year Revenue: Reaffirmed range of $20 million to $22 million, representing ~55% year-over-year growth at the midpoint; YTD revenue (9 months) was $13.8 million.
• 2026 Full-Year Gross Margin: Raised low-end guidance to 52.5% to 55% (previously 50%–55%); YTD margin was 53.3%.
• 2026 Full-Year Net Cash Burn: Reaffirmed range of $26 million to $28 million, representing ~10% year-over-year decline; Q3 burn was $5.6 million.
• Cash Runway: Projects cash runway extending into 2028 assuming no additional financing or debt draws; balance sheet holds $37.9 million cash/equivalents as of Sept 30, 2026.
• Debt Facility: Retains $25 million of remaining capacity in existing loan agreement.

Business-Segment Outlook:

• U.S. Hospitals & IDNs: Anticipates growth driven by the first full annual capital planning cycle since Model 2 launch; expansion of use cases from ICU to ED, clinics, and operating rooms; follow-on orders expected to materialize 2–3 quarters post-initial placement in national systems.
• Neurology Offices & Concierge: Expect continued adoption and reactivation of prior prospects once contrast imaging is cleared; contrast indication expected to drive unit orders by enabling dedicated CPT code 70553 reimbursement in outpatient settings.
• International: Model 2 rollout in Europe, UK, and Middle East (Kuwait/UAE) expected to contribute to future quarters; expansion pace depends on local distributor adoption rates.
• Unit Sales: Targeting steady growth of approximately two units per quarter throughout the remainder of 2026; Q3 saw 14 units sold.

Market and Competitive Outlook:

• Pricing & ASP: Record average selling prices (ASPs) sustained in Q3 2026 due to Model 2 mix and pricing increases implemented at launch and early 2026; management views pricing power as durable and substantiated by ROI metrics.
• Competitive Position: Building a "land and expand" model where initial clinical champions drive system-wide adoption; contrast imaging expected to create a "tailwind" for site-of-care expansion (OR, ED) and office placement.
• Market Dynamics: Identifying a shift from purely critical care (ICU) to broader routine use; demand driven by patient boarding issues and need for decentralized imaging.

Macro / Industry Outlook:

• Regulatory (FDA): On track to submit 510K application for contrast imaging by year-end 2026; statutory review time of 90 days suggests clearance likely in Q2 2027 or mid-2027.
• Clinical Evidence: Recent publication of Neuro-PMR study (92% concordance with conventional MRI) supports office and hospital adoption; contrast study enrollment complete.
• Industry Trends: Healthcare expansion into wellness, longevity, and prevention creates a "fourth vertical" opportunity; AI and robotics are cited as major tailwinds for decentralizing brain imaging.

Strategic Initiatives:

• Product Launches: Model 2 launched in U.S. hospitals and international markets (Europe/UK/Middle East); OptiFai software received CE/UKCA marking in October.
• R&D Focus: Investments directed toward OptiFai AI software, contrast imaging approval, and future consumer-facing AI/cloud reporting tools for the brain wellness vertical.
• Wellness Vertical: Developing a "brain wellness/longevity" platform (consumer-facing reporting) expected to generate revenue starting 2028; no revenue bake expected for 2027.
• Commercial Expansion: Planning to optimize sales organization structure for 2027; anticipating modest investments in commercial bandwidth (no doubling/tripling of headcount) to capture office and wellness opportunities.

Risks and Headwinds to Outlook:

• Sales Cycle Length: Extended procurement, legal, cybersecurity, and AI vetting processes for health systems may delay conversions, particularly in national IDNs.
• Capital Budgeting: Customer orders may be delayed to the following year if capital budgets are already allocated, creating timing mismatches.
• Regulatory Timing: FDA 510K clearance for contrast is projected for mid-2027; delays could impact office adoption timelines.
• International Rollout: Speed of international market penetration varies by distributor and country infrastructure.

Management Tone on the Future:

• Confidence Level: High confidence in the "new trajectory," citing "strong commercial performance," "identifiable tailwinds," and "durable margin gains."
• Progress: Describes Q3 as the "beginning of a new trajectory" with record revenue, margin, and cash efficiency; notes the first time quarterly revenue exceeded cash burn.
• Hedges: Reaffirmed 2026 guidance despite strong Q3, citing seasonality and the absence of last year's one-time multi-unit upgrade in Q4 2025; explicitly states no revenue expectations for the wellness vertical in 2027.
• Strategic Shift: Management emphasizes a transition from a "niche medical technology company" to a "broad-based medical and wellness platform."

Miscellaneous:

• Non-Cash Items: Q3 2026 net loss included a $1.5 million non-cash gain from warrant liabilities changes (vs. $2.3 million loss in prior year).
• Share Count/Buybacks: No mention of share count targets, dividends, or buyback programs in the transcript.
• Capex/Opex: Operating expenses increased <2% in Q3 despite 53% revenue growth; R&D and G&A maintained discipline with flat-to-modest growth expected in 2027.